Beth C Seidenberg
Director at PGNY; Director at VERA; Director, 10% owner at Epizyme, Inc.
Filed with the SEC as SEIDENBERG BETH C
- Sold, on record
- $16M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Oct 28, 2024
- Form 144 notices
- 4
- Proposed sales
- Quarters with a sale
- 0 of the last 8
- No sale in two years
- Companies
- 3
- Filed as an executive or holder
Companies
- PGNYProgyny, Inc.Director
- VERAVera Therapeutics, Inc.Director
- Epizyme, Inc.Director, 10% owner
Sales by reason
2
Routine
2
Plan not stated
0
No plan
3
Unusual
Form 4 sales per year, every sale on record.
Sales by company
- Epizyme, Inc.388,584 shares
- PGNY95,050 shares
- VERA31,476 shares
Shares sold, every Form 4 sale on record.
Timeline
- Dec 9, 2024Notice
Filed a notice to sell 39,680 shares
$628k39,680 shares
- Oct 28, 2024Routine
Sold 10.2% of their holdings
$720k15,000 shares at $48.03
- Oct 28, 2024Notice
Filed a notice to sell 15,000 shares
$616k15,000 shares
- Sep 19, 2024Routine
Sold 10.1% of their holdings
$696k16,476 shares at $42.26
- Sep 18, 2024Notice
Filed a notice to sell 15,000 shares
$600k15,000 shares
- Sep 18, 2024Notice
Filed a notice to sell 1,476 shares
$59k1,476 shares
- Apr 15, 2021Plan not stated
Sold 0.2% of their holdings
$912k18,127 shares at $50.32
- Dec 14, 2020Unusual
Sold 100% of their holdings
$1.6M38,461 shares at $42.00
- Nov 27, 2020Unusual
Sold 33.3% of their holdings
$692k19,231 shares at $36.00
- Aug 11, 2020Unusual
Sold 25% of their holdings
$577k19,231 shares at $30.00
10 of 11
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Aug 10, 2026 | LTGO | Director, 10% owner | ConvertedSeries Seed Convertible Stock | 12.7M | 0 | SEC | ||
| Aug 10, 2026 | Aug 10, 2026 | LTGO | Director, 10% owner | Converted | 12.7M | 2.1M | SEC | ||
| Jun 12, 2026 | Jun 15, 2026 | SGMT | Director | AwardedStock Option (Right to Buy) | 39,567 | 39,567 | SEC | ||
| May 27, 2026 | May 29, 2026 | KYTX | Director | AwardedStock Option (right to buy) | 20,582 | 20,582 | SEC | ||
| May 27, 2026 | May 29, 2026 | KYTX | Director | Awarded | 5,093 | 21,727 | SEC | ||
| May 21, 2026 | May 26, 2026 | VERA | Director | AwardedStock Option (right to buy) | 17,084 | 17,084 | SEC | ||
| Dec 18, 2025 | Dec 22, 2025 | KYTX | Director | Bought | 133,333 | $7.50 | $1000k | 869,317 | SEC |
| Jun 9, 2025 | Jun 10, 2025 | SGMT | Director | AwardedStock Option (Right to Buy) | 60,772 | 32,250 | SEC | ||
| May 29, 2025 | Jun 2, 2025 | KYTX | Director, 10% owner | AwardedStock Option (right to buy) | 65,351 | 65,351 | SEC | ||
| May 29, 2025 | Jun 2, 2025 | KYTX | Director, 10% owner | Awarded | 16,634 | 16,634 | SEC | ||
| May 21, 2025 | May 23, 2025 | SLRN | Director | Returned to the companyDirector Stock Option (right to buy) | 115,401 | 0 | SEC | ||
| May 21, 2025 | May 23, 2025 | SLRN | Director | Returned to the company | 9.9M | 0 | SEC | ||
| May 14, 2025 | May 16, 2025 | VERA | Director | AwardedStock Option (right to buy) | 14,000 | 14,000 | SEC | ||
| Oct 28, 2024 | Oct 30, 2024 | VERA | Director | Sold | 15,000 | $48.03 | $720k | 131,553 | SEC |
| Sep 19, 2024 | Sep 20, 2024 | VERA | Director | Sold | 16,476 | $42.26 | $696k | 146,553 | SEC |
| Jun 7, 2024 | Jun 11, 2024 | SLRN | Director | AwardedDirector Stock Option (right to buy) | 92,158 | 92,158 | SEC | ||
| Jun 5, 2024 | Jun 7, 2024 | SGMT | Director | AwardedStock Option (Right to Buy) | 51,459 | 51,459 | SEC | ||
| May 23, 2024 | May 28, 2024 | PGNY | Director | AwardedStock Option (Right to Buy) | 26,926 | 26,926 | SEC | ||
| May 23, 2024 | May 28, 2024 | PGNY | Director | Awarded | 7,206 | 43,416 | SEC | ||
| May 15, 2024 | May 17, 2024 | VERA | Director | AwardedStock Option (right to buy) | 14,000 | 14,000 | SEC | ||
| Feb 12, 2024 | Feb 14, 2024 | KYTX | Director, 10% owner | ConvertedSeries A-1 Redeemable Convertible Preferred Stock | 20.6M | 0 | SEC | ||
| Feb 12, 2024 | Feb 14, 2024 | KYTX | Director, 10% owner | Converted | 4.5M | 735,984 | SEC | ||
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | Bought | 46,875 | $16.00 | $750k | 46,875 | SEC |
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | Returned to the companyStock Option (Right to Buy) | 23,216 | 0 | SEC | ||
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | Returned to the company | 38,763 | 0 | SEC | ||
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | ConvertedSeries A Preferred Stock | 155M | 0 | SEC | ||
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | Converted | 1.9M | 84,768 | SEC | ||
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | AwardedStock Option (Right to Buy) | 23,216 | 23,216 | SEC | ||
| Jul 18, 2023 | Jul 20, 2023 | SGMT | Director | Awarded | 38,763 | 38,763 | SEC | ||
| Jun 23, 2023 | Jun 27, 2023 | PGNY | Director | Other | 27,446 | 36,210 | SEC | ||
| Jun 9, 2023 | Jun 13, 2023 | PGNY | Director | Other | 1.9M | 25,926 | SEC | ||
| May 31, 2023 | Jun 2, 2023 | ATRA | Director | AwardedNon-Qualified Stock Option (Right to Buy) | 79,500 | 79,500 | SEC | ||
| May 31, 2023 | Jun 2, 2023 | ATRA | Director | Awarded | 57,000 | 115,689 | SEC | ||
| May 24, 2023 | Jun 1, 2023 | PGNY | Director | AwardedStock Option (Right to Buy) | 22,970 | $2.83 | $65k | 3,261 | SEC |
| May 24, 2023 | Jun 1, 2023 | PGNY | Director | Awarded | 5,116 | 19,270 | SEC | ||
| May 10, 2023 | May 12, 2023 | VERA | Director | AwardedStock Option (right to buy) | 20,000 | 20,000 | SEC | ||
| May 9, 2023 | May 11, 2023 | SLRN | Director, 10% owner | Bought | 1.3M | $18.00 | $23.6M | 60,000 | SEC |
| May 9, 2023 | May 11, 2023 | SLRN | Director, 10% owner | OtherDirector Stock Option (right to buy) | 46,486 | 23,243 | SEC | ||
| May 9, 2023 | May 11, 2023 | SLRN | Director, 10% owner | ConvertedSeries A Redeemable Convertible Preferred Stock | 8.5M | 0 | SEC | ||
| May 9, 2023 | May 11, 2023 | SLRN | Director, 10% owner | Converted | 8.5M | 8.5M | SEC | ||
| May 4, 2023 | May 4, 2023 | SLRN | Director, 10% owner | AwardedDirector Stock Option (right to buy) | 23,243 | 23,243 | SEC | ||
| Mar 30, 2023 | Apr 3, 2023 | VERA | Director | Bought | 2,300 | $7.24 | $17k | 1.9M | SEC |
| Mar 28, 2023 | Mar 30, 2023 | VERA | Director | Bought | 23,908 | $7.24 | $173k | 1.9M | SEC |
| Mar 27, 2023 | Mar 28, 2023 | VERA | Director | Bought | 3,466 | $7.24 | $25k | 1.9M | SEC |
| Mar 20, 2023 | Mar 21, 2023 | VERA | Director | Bought | 89,297 | $7.14 | $637k | 1.9M | SEC |
| Mar 16, 2023 | Mar 17, 2023 | VERA | Director | Bought | 92,941 | $7.10 | $660k | 1.8M | SEC |
| Mar 10, 2023 | Mar 14, 2023 | VERA | Director | Bought | 48,003 | $7.16 | $344k | 1.7M | SEC |
| Mar 3, 2023 | Mar 7, 2023 | VERA | Director | Bought | 1,000 | $7.25 | $7k | 1.7M | SEC |
| Mar 2, 2023 | Mar 3, 2023 | VERA | Director | Bought | 23,478 | $7.24 | $170k | 1.7M | SEC |
| Feb 23, 2023 | Feb 27, 2023 | VERA | Director | Bought | 200 | $7.24 | $1k | 1.7M | SEC |
Page 1
Sales and notices (11)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dec 9, 2024 | Dec 9, 2024 | PGNY | Director | Form 144 notice | 39,680 | $628k | Notice | SEC | |
| Oct 28, 2024 | Oct 30, 2024 | VERA | Director | Form 4 sale | 15,000 | $720k | 10.2% | Routine | SEC |
| Oct 28, 2024 | Oct 28, 2024 | VERA | Director | Form 144 notice | 15,000 | $616k | Notice | SEC | |
| Sep 19, 2024 | Sep 20, 2024 | VERA | Director | Form 4 sale | 16,476 | $696k | 10.1% | Routine | SEC |
| Sep 18, 2024 | Sep 18, 2024 | VERA | Director | Form 144 notice | 15,000 | $600k | Notice | SEC | |
| Sep 18, 2024 | Sep 18, 2024 | VERA | Director | Form 144 notice | 1,476 | $59k | Notice | SEC | |
| Apr 15, 2021 | Apr 19, 2021 | PGNY | Director | Form 4 sale | 18,127 | $912k | 0.2% | Plan not stated | SEC |
| Dec 14, 2020 | Dec 15, 2020 | PGNY | Director | Form 4 sale | 38,461 | $1.6M | 100.0% | Unusual | SEC |
| Nov 27, 2020 | Dec 1, 2020 | PGNY | Director | Form 4 sale | 19,231 | $692k | 33.3% | Unusual | SEC |
| Aug 11, 2020 | Aug 13, 2020 | PGNY | Director | Form 4 sale | 19,231 | $577k | 25.0% | Unusual | SEC |
| Feb 10, 2014 | Feb 12, 2014 | Epizyme, Inc. | Director, 10% owner | Form 4 sale | 388,584 | $10.7M | 9.2% | Plan not stated | SEC |